Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-γ

Anatomical Record - Part A Discoveries in Molecular, Cellular, and Evolutionary Biology

Volumn 288, Issue 12, 2006, Pages 1303-1309

  Hrubec, Terry C ^a,b   Yan, Mingjin ^c   Ye, Keying ^d   Salafia, Carolyn M ^e   Holladay, Steven D ^b  

^a EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c Medtronic Sofamor Danek   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e Columbia University Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; TERATOGENIC AGENT; VALPROIC ACID;

ANENCEPHALUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDICATION; EXENCEPHALY; EYE MALFORMATION; FEMALE; FETUS; FETUS MALFORMATION; GESTATIONAL AGE; IMMUNOSTIMULATION; MALE; MENTAL DISEASE; MOUSE; MOUSE STRAIN; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEIZURE; SINGLE DRUG DOSE; SPINA BIFIDA;

ABNORMALITIES, DRUG-INDUCED; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EYELID DISEASES; EYELIDS; FEMALE; FETAL DEATH; FETAL RESORPTION; FETAL WEIGHT; GESTATIONAL AGE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; MICE; NEURAL TUBE DEFECTS; PLACENTA; PREGNANCY; TIME FACTORS; VALPROIC ACID;

EID: 33845441561     PISSN: 0003276X     EISSN: 15524892     Source Type: Journal    
DOI: 10.1002/ar.a.20397     Document Type: Article

References (36)

1. Al Deeb S, Al Moutaery K, Arshaduddin M, Tariq M. 2000. Vitamin E decreases valproic acid induced neural tube defects in mice. Neurosci Lett 292:179-182.
2. Beck SL. 1999. Contributions of dam and conceptus to differences in sensitivity to valproic acid among C57 black and SWV mice. Reprod Toxicol 13:353-360.
3. Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH. 2000. Valproic acid-induced alterations in growth and neurotrophic factor. Reprod Toxicol 14:1-11.
4. Cederberg J, Picard JJ, Eriksson UJ. 2003. Maternal diabetes in the rat impairs the formation of neural-crest derived cranial nerve ganglia in the offspring. Diabetologia 46:1245-1251.
5. Craig JC, Bennett GD, Miranda RC, Mackler SA, Finnell RH. 2000. Ribonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid induced neural tube defects in mice. Teratology 61:305-313.
6. Da Costa M, Sharon M. 1980. The synthesis of folate binding protein in lymphpcytes during transformation. Br J Haematol 46:575-579.
7. Dawson JE, Raymond AM, Winn LM. 2006. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol. 211:124-132.
8. DeSesso JM, Scialli AR, Holson JF. 1999. Apparent lability of neural tube closure in laboratory animals and humans. Am J Med Gen 87:143-161.
9. Ehlers K, Elmazar MM, Nau H. 1996. Methionine reduces the valproic acid induced spina bifida rate in mice without altering valproic acid kinetics. J Nutr 126:67-75.
10. Emmanouil-Nikoloussi EN, Foroglou NG, Kerameos-Foroglou CH, Thliveris JA. 2004. Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie 88:41-45.
11. Eskes TKAB, Mooij PNM, Steegers-Theunissen RPM, Lips JP, Pasker-de Jong PCM. 1992. Prepregnancy care and prevention of birth defects. J Perinat Med 20:253-265.
12. Fleming A, Copp AJ. 1998. Embryonic folate metabolism and mouse neural tube defects. Science 280:2107-2109.
13. Hishida R, Nau H. 1998. VPA induced neural tube defects in mice: I, altered metabolism of sulfur amino acids and glutathione. Teratog Carcinog Mutagen 18:49-61.
14. Holladay SD, Sharova LV, Smith BJ, Gogal RM Jr, Ward DL, Blaylock BL. 2000. Non-specific stimulation of the maternal immune system: I, effects on teratogen-induced fetal malformations. Teratology 62:413-419.
15. Hrubec TC, Punareewattana K, Prater MR, Holladay SD. 2006a. Reduction of teratogen induced birth defects in mice: role of maternal immune stimulation. Curr Topics Toxicol (in press).
16. Hrubec TC, Prater MR, Toops KA, Holladay SD. 2006b. Reduction in diabetes induced craniofacial defects by maternal immune stimulation. Birth Def Res B Dev Repro Toxicol 77:1-9.
17. Kennedy D, Koren G. 1998. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psycho Neurosci 23:223-228.
18. Khera KS. 1992. Valproic acid-induced placental and teratogenic effects in rats. Teratology 45:603-610.
19. Kramer CY. 1956. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:307-310.
20. Laudermilch CL, Holladay SD, Sponenberg DP, Saunders GK, Ward DL, Prater MR. 2005. Placental improvement and reduced distal limb defects by maternal interferon-gamma injection in methylnitrosourea-exposed mice. Birth Def Res A Clin Mol Teratol 73:597-604.
21. Martin ML, Regan CM. 1991. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 1991. 554: 223-228.
22. Nomura T, Hata S, Kusafuka T. 1990. Suppression of developmental anomalies by maternal macrophages in mice. J Exp Med 172:1325-1330.
23. Padmanabhan R, Shafiullah MM. 2003. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom 43:29-40.
24. Prater MR, Strahl ED, Zimmerman KL, Ward DL, Holladay SD. 2004. Reduced birth defects caused by maternal immune stimulation in methylnitrosourea-exposed mice: association with placental improvement. Birth Def Res A Clin Mol Teratol 70:862-869.
25. Punareewattana K, Sharova LV, Li W, Ward DL, Holladay SD. 2003. Reduced birth defects caused by maternal immune stimulation may involve increased expression of growth promoting genes and cytokine GM-CSF in the spleen of diabetic ICR mice. Int Immunopharmacol 3:1639-1655.
26. Punareewattana K, Holladay SD. 2004. Immunostimulation by complete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, or interferon-γ reduces severity of diabetic embryopathy in ICR mice. Birth Def Res A Clin Mol Teratol 70:20-27.
27. Sharova L, Sura P, Smith BJ, Gogal RM Jr, Sharov AA, Ward DL, Holladay SD. 2000. Nonspecific stimulation of the maternal immune system: II, effects on gene expression in the fetus. Teratology 62:420-128.
28. Sharova LV, Gogal RM Jr, Sharova AA, Crisman MV, Holladay SD. 2002. Immune stimulation in urethane-exposed pregnant mice increases expression of level of spleen leukocyte genes for TGFb3, GM-CSF and other cytokines that may play a role in reduced chemical-induced birth defects. Int Immunopharmacol 2:1477-1489.
29. Sharova LV, Sharova AA, Sura P, Gogal RM Jr, Smith BJ, Holladay SD. 2003. Maternal immune stimulation reduces both placental morphologic damage and down-regulated placental growth factor and cell cycle gene expression caused by urethane: are these events related to reduced teratogenesis? Int Immunopharmacol 3:945-955.
30. Spiegelstein O, Merriweather MY, Wicker NJ, Finnell RH. 2003. Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. Birth Def Res A Clin Mol Teratol 67:974-978.
31. Tang LS, Finnell RH. 2003. Neural and orofacial defects in Folp1 knockout mice. Birth Def Res A Clin Mol Teratol 67:209-218.
32. Torchinsky A, Toder V, Savion S, Shepshelovich J, Orenstein H, Fein A. 1997. Immunostimulation increases the resistance of mouse embryos to the teratogenic effect of diabetes mellitus. Diabetologia 40:635-640.
33. Tukey JW. 1953. The problem with multiple comparisons: unpublished manuscript in the collected works of John W Tukey VIII - multiple comparisons, 1948-1983. New York: Chapman and Hall, p 1-300
34. van Poppel G, van den Berg H. 1997. Vitamins and cancer. Cancer Lett 114:195-202.
35. Wagner C, Nau H. 1991. Diurnal variation of folate concentration in mouse embryo and plasma: the protective effect of folinic acid on valproic acid induced teratogenicity is time dependent. Repro Tox 5:465-171.
36. Wlodarczyk BC, Craig JC, Bennett GD, Calvin JA, Finnell RH. 1996. Valproic acid induced changes in gene expression during neurulation in a mouse model. Teratology 54:284-297.